Navigation Links
Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors

cGMP manufacturing facility.

Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its INGN 241 clinical development program for treatment of cancer. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: www.introgen.com.

Contact

Introgen Therapeutics, Inc., Austin
C. Channing Burke, 512-708-9310, ext. 322
c.burke@introgen.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
3. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...
(Date:5/23/2013)... BOSTON , May 23, 2013  PAREXEL International ... it will be presenting at the Jefferies Healthcare Conference ... Vice President and Chief Financial Officer, will be ... at 1:30 p.m. ET on Monday, June 3, 2013. ... available through the "Investors" section of PAREXEL,s website at ...
(Date:5/23/2013)... Mai 2013 Ranbaxy Laboratories ... von Daiichi Sankyo Co., Ltd. (im ... Mai die Maßnahmen bekannt, die Ranbaxy ... um sich der Angelegenheiten der vorhergehenden ... ). Daiichi Sankyo unterstützt ...
Breaking Medicine Technology:Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3PAREXEL International To Present At Jefferies Healthcare Conference 2Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an 2
... March 23 Magellan Biosciences, Inc., an emerging ... has become the first to offer minocycline and telavancin ... and Drug Administration (FDA) has cleared TREK-brand Sensititre MIC ... negative bacterial isolates, as well as telavancin against Gram ...
... and MORRISTOWN, N.J. , March 23 MicroMass Communications, Inc., a world leader in behavioral marketing, ... be supporting the launch of the new center and its mission of promoting the growth of North Carolina ,s ... ... , , ...
Cached Medicine Technology:FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 2FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 3FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 4MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 2MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 3MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 4
(Date:5/23/2013)... human pathogen that can cause rapidly progressing, life threatening ... "Until now we have not known how it attaches ... mystery how it attaches to the airway to colonise", ... get any symptoms, while some people progress to invasive ... the detail of how the bacterium colonises the airway. ...
(Date:5/23/2013)... Gray HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay ... used to save an infant born with a serious airway ... of bioengineering and surgery. A report in the May ... situation that sparked the innovation. At first, the baby ... to have difficulty breathing and eating when he was 6 ...
(Date:5/23/2013)... 2013 DRE, Inc. is now offering ... a solution to upgrade older model DRE or BFW ... lighting system. , DRE and BFW customers can ... BFW halogen headlights to LED with DRE’s American-made Xavier-C3 ... Conversion Kit provides a bright, clean and even field ...
(Date:5/23/2013)... In Florida, residents have not been hit with a ... Florida’s good luck will continue, warns Rick Knabb, Director of ... residents, it is important to prepare as if one could ... to be a 50-percent chance that a major hurricane could ... from June 1 to November 30 in Florida, this makes ...
(Date:5/23/2013)... The latest report from Insure.com , a leading insurance ... of the country when it comes to auto insurance rates. ... that of the national average of $1,500. Although a variety ... from state to state, there are certain characteristics of Louisianan ... Compared to the rest of the country, according to ...
Breaking Medicine News(10 mins):Health News:New discovery in fight against deadly meningococcal disease 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 3Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 2Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 3Health News:As Hurricane Season Nears, Skylake Insurance Encourages Florida Residents To Prepare Early For Safety 2Health News:Cunningham Financial Group Wants Motorists to Understand Their Rates as Louisiana’s Auto Insurance Rates Remain the Highest in the Nation 2
... , FRIDAY, Aug. 12 (HealthDay News) -- Obstructive sleep apnea ... positive airway pressure (CPAP) machines, a new study finds. ... is interrupted many times during sleep due to the repeated ... by pumping a continuous stream of air through a mask ...
... Joslin Diabetes Center and Children,s Hospital Boston have shown that ... in varying amounts in children increasing until puberty and ... The study used PET imaging data to document children,s ... burns energy instead of storing it. Results were published in ...
... HealthDay Reporter , THURSDAY, Aug. 11 (HealthDay News) -- ... temporary tattoo can pick up and transmit physiological signals such ... new advance in "wearable electronics" might one day replace the ... body functions. "I can,t feel its presence," said John ...
... some past studies have shown that persons carrying a few ... counterparts, a new study that measured subjects, weight at multiple ... Research from Adventist Health Studies recently published in ... that men over 75 with a body mass index (BMI) ...
... , THURSDAY, Aug. 11 (HealthDay News) -- The HIV ... a high prevalence of AIDS is 10 to 20 times ... government report indicates. Two percent of poor heterosexuals in ... Disease Control and Prevention researchers, analysis of National HIV Behavioral ...
... By isolating cells from patients, spinal tissue within a few ... Health have developed a new model of the paralyzing disease ... disease, cells called astrocytes become toxic to nerve cells ... humans. The new model could be used to investigate ...
Cached Medicine News:Health News:'Good fat' most prevalent in thin children 2Health News:Medical Tattoo Tracks Body Functions 2Health News:Medical Tattoo Tracks Body Functions 3Health News:Contrary to earlier findings, excess body fat in elderly decreases life expectancy 2Health News:Poor, Urban Heterosexuals at High Risk of HIV: CDC 2Health News:New model of ALS is based on human cells from autopsied tissue 2Health News:New model of ALS is based on human cells from autopsied tissue 3Health News:New model of ALS is based on human cells from autopsied tissue 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: